Roivant Jumps 24% Premarket After Positive Phase 2 Mosliciguat Data; Novartis Falls 12%

According to CNBC, Roivant Sciences shares rallied 24% premarket after the company said Phase 2 trial results for subsidiary Pulmovant's mosliciguat showed a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance in patients with pulmonary hypertension with interstitial lung disease. Lockheed Martin rose 0.7% after UBS upgraded the defense contractor to buy from neutral, citing underappreciated earnings growth potential. Novartis fell 12% after Phase 3 results showed its del-desiran drug did not produce significant improvement in patients with myotonic dystrophy type 1. Peloton Interactive dropped more than 4% after Morgan Stanley downgraded the stock to underweight from equal weight and said PTON is facing structural headwinds in fitness. Boston Scientific slipped more than 2% after the company said a recent cyberattack likely affected sales and profit targets for 2026.